Last reviewed · How we verify
Grastofil®
Grastofil is a granulocyte colony-stimulating factor (G-CSF) analog that stimulates the production and release of neutrophils from bone marrow to reduce infection risk in cancer patients receiving chemotherapy.
Grastofil is a granulocyte colony-stimulating factor (G-CSF) analog that stimulates the production and release of neutrophils from bone marrow to reduce infection risk in cancer patients receiving chemotherapy. Used for Chemotherapy-induced neutropenia in cancer patients.
At a glance
| Generic name | Grastofil® |
|---|---|
| Also known as | biosimilar filgrastim |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
| Drug class | Granulocyte colony-stimulating factor (G-CSF) analog |
| Target | G-CSF receptor (CSF3R) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Grastofil binds to G-CSF receptors on hematopoietic progenitor cells, promoting their differentiation and proliferation into mature neutrophils. By increasing circulating neutrophil counts, it reduces the duration and severity of chemotherapy-induced neutropenia, thereby lowering the incidence of febrile neutropenia and associated infections in cancer patients.
Approved indications
- Chemotherapy-induced neutropenia in cancer patients
Common side effects
- Bone pain
- Headache
- Fatigue
- Injection site reactions
Key clinical trials
- Lapelga vs Gastrofil (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |